A novel phosphoramide compound, DCZ0805, shows potent anti-myeloma activity via the NF-κB pathway
Abstract Background Multiple myeloma (MM) is a highly aggressive and incurable clonal plasma cell disease with a high rate of recurrence. Thus, the development of new therapies is urgently needed. DCZ0805, a novel compound synthesized from osalmide and pterostilbene, has few observed side effects. I...
Main Authors: | Xuejie Gao, Bo Li, Anqi Ye, Houcai Wang, Yongsheng Xie, Dandan Yu, Zhijian Xu, Bingqing Shi, Hui Zhang, Qilin Feng, Ke Hu, Yong Zhang, Cheng Huang, Guang Yang, Jumei Shi, Weiliang Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-05-01
|
Series: | Cancer Cell International |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12935-021-01973-1 |
Similar Items
-
A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe
by: Liangning Hu, et al.
Published: (2020-06-01) -
DCZ0814 induces apoptosis and G0/G1 phase cell cycle arrest in myeloma by dual inhibition of mTORC1/2
by: Kong Y, et al.
Published: (2019-05-01) -
Curcumin Enhances Cytotoxic Effects of Bortezomib in Human Multiple Myeloma H929 Cells: Potential Roles of NF-κB/JNK
by: Qing-Xian Bai, et al.
Published: (2012-04-01) -
The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo
by: Liang Zhou, et al.
Published: (2019-03-01) -
Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway
by: Li Yang, et al.
Published: (2018-02-01)